Cocrystal Pharma【COCP】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.895

買値

1.89

売値

1.90

出来高

1,683

1.87 日の範囲 1.905

1.325 52 週間の範囲 3.26

時価総額

19.279M

前日終値

1.87

始値

1.88

時刻

1.8998

最終取引時間

01:00:18

財務取引量

US$ 3,177

VWAP

1.8875

平均取引量 (3 か月)

45,054

発行済株式数

10,173,790

配当利回り

PER

-1.07

1 株当たり利益 (EPS)

-1.77

歳入

2.6M

純利益

-17.98M

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first... Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.cocrystalpharma.com

本社

Wilmington, Delaware, USA

設立

Cocrystal Pharma Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker COCP. The last closing price for Cocrystal Pharma was US$1.87. Over the last year, Cocrystal Pharma shares have traded in a share price range of US$ 1.325 to US$ 3.26.

Cocrystal Pharma currently has 10,173,790 shares in issue. The market capitalisation of Cocrystal Pharma is US$19.02 million. Cocrystal Pharma has a price to earnings ratio (PE ratio) of -1.07.

Form 8-K - Current report

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025...

Form 8-K - Current report

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30...

Form 8-K - Current report

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current influenza vaccines offer no protection...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.155	-7.56097560976	2.05	2.08	1.87	10371	1.96804968	CS
4	-0.455	-19.3617021277	2.35	2.6	1.87	22568	2.08791058	CS
12	0.125	7.06214689266	1.77	3.26	1.65	45054	2.30625741	CS
26	0.2229	13.3305424317	1.6721	3.26	1.6	29030	2.15867897	CS
52	0.345	22.2580645161	1.55	3.26	1.325	26734	2.10774744	CS
156	-4.6846	-71.1988570734	6.5796	7.5588	1.325	82796	4.29189908	CS
260	-5.545	-74.5295698925	7.44	49.2	1.325	2021542	18.94305586	CS

COCP - Frequently Asked Questions (FAQ)

What is the current Cocrystal Pharma share price?

The current share price of Cocrystal Pharma is US$ 1.895

How many Cocrystal Pharma shares are in issue?

Cocrystal Pharma has 10,173,790 shares in issue

What is the market cap of Cocrystal Pharma?

The market capitalisation of Cocrystal Pharma is USD 19.02M

What is the 1 year trading range for Cocrystal Pharma share price?

Cocrystal Pharma has traded in the range of US$ 1.325 to US$ 3.26 during the past year

What is the PE ratio of Cocrystal Pharma?

The price to earnings ratio of Cocrystal Pharma is -1.07

What is the cash to sales ratio of Cocrystal Pharma?

The cash to sales ratio of Cocrystal Pharma is 7.43

What is the reporting currency for Cocrystal Pharma?

Cocrystal Pharma reports financial results in USD

What is the latest annual turnover for Cocrystal Pharma?

The latest annual turnover of Cocrystal Pharma is USD 2.6M

What is the latest annual profit for Cocrystal Pharma?

The latest annual profit of Cocrystal Pharma is USD -17.98M

What is the registered address of Cocrystal Pharma?

The registered address for Cocrystal Pharma is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Cocrystal Pharma website address?

The website address for Cocrystal Pharma is www.cocrystalpharma.com

Which industry sector does Cocrystal Pharma operate in?

Cocrystal Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
CAPTCaptiVision Inc	US$ 1.48 (237.13%)	99.78M
VLCNVolcon Inc	US$ 6.1199 (83.23%)	37.37M
QNTMQuantum Biopharma Ltd	US$ 4.93 (55.03%)	36.71M
PTIRGraniteShares 2X Long PLTR Daily ETF	US$ 234.25 (50.82%)	1.01M
PLTUDirexion DAily PLTR Bull 2X Shares	US$ 49.66 (50.53%)	1.4M
OMGAOmega Therapeutics Inc	US$ 0.224175 (-53.21%)	2.75M
UPCUniverse Pharmaceuticals Inc	US$ 0.275282 (-34.05%)	1.1M
VIRXViracta Therapeutics Inc	US$ 0.052 (-33.16%)	3.02M
PLTDDirexion Daily PLTR Bear 1X Shares	US$ 15.24 (-25.59%)	4.74M
TWNPTwin Hospitality Group Inc	US$ 10.75 (-23.27%)	121.72k
PLTRPalantir Technologies Inc	US$ 105.245 (25.68%)	100.38M
CAPTCaptiVision Inc	US$ 1.48 (237.13%)	99.78M
NVDANVIDIA Corporation	US$ 120.1667 (3.01%)	90.22M
RGTIRigetti Computing Inc	US$ 14.02 (4.08%)	84.32M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.1639 (-15.91%)	65.11M